Dublin, Feb. 08, 2016 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/7ft9d9/microbiome) has announced the addition of the "Microbiome Therapeutics Market, 2015 - 2030" report to their offering.

The Microbiome Therapeutics Market, 2015-2030' report provides a comprehensive study on the current landscape and the future outlook of the evolving pipeline of products in this area. Imbalance in the natural microbiota are a known cause for many chronic diseases such as antibiotic associated diarrhoea (AAD), Clostridium difficileinfections (CDI), irritable bowel syndrome (IBS), diabetes, Crohn's disease and ulcerative colitis.

While the field has gathered the interest of several companies, there are no approved microbiome drugs available in the market yet; FMT is the only commercially available therapy. The development pipeline of microbiome therapeutics, though, has several promising candidates that are likely to result in commercial success stories in the foreseen future.

Among other elements, the report also elaborates on new microbiome based diagnostic solutions being developed and the upcoming opportunities in this market for different stakeholders. As pharmaceutical companies continue to initiate and expand their research programs in this area, one of the key objectives outlined for this report was to understand the future potential of the market.

This was done by analysing:

- The microbiome therapeutic pipeline in terms of phase of development, type of products and indications.
- The epidemiology, patient population and available treatment plans for the potential therapeutic areas in this field.
- Partnerships that have taken place in the recent past covering research and development collaborations, product development and commercialisation agreements, license agreements, acquisitions and other relevant agreements.
- Various investments and grants received by companies focused in this area.
- The likely adoption of the microbiome therapeutics, the competition posed by the current treatment plans and the expected growth rate over the coming few years.

The study provides a detailed market forecast and opportunity analysis for the short-mid term (2015-2022) and long term (2022-2030). The research, analysis and insights presented in this report include potential sales of FMT therapies and drugs in late stages of development. Our opinions and insights, presented in this study, were influenced by several discussions we conducted with experts in this area.

These included senior representatives at Assembly Biosciences, Da Volterra, Metabiomics, MicroBiome Therapeutics and Rebiotix. All actual figures have been sourced and analysed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights


- Overall, we have identified more than 100 microbiome products, in clinical and preclinical stages,which are being developed as therapeutic interventions for various disease areas. A healthy 27% of the pipeline accounts for molecules in clinical development; of these, majority are in phase II.
- In addition, we have captured several start-ups and small-sized firms that have taken initiatives in developing innovative microbiome based therapeutics. Notable examples include (in alphabetical order) AOBiome, Avid Biotics, C3 Jian, Da Volterra, OpenBiome, Procarta Biosystems, Rebiotix, Ritter Pharmaceuticals, Quorum Innovations, Seres Therapeutics, Symbiotic Health, Vedanta Biosciences, Xycrobe Therapeutics.
- Several firms are also developing microbiome related diagnostics and companion diagnostics. Examples include (in alphabetical order) Admera Health, Biocartis, Enterome Bioscience, Human Longevity, Metabiomics, Microbiome Diagnostics, Viomer, Whole Biome.
- Encouraging clinical results and unexplored opportunities have yielded an intense framework of investment activity with a sizeable number of venture capitalists actively supporting the research. In fact, during 2014 and 2015, there have been investments (equity + debt) of close to USD 0.7 billion.
- The microbiome therapeutics market is anticipated to grow aggressively with a healthy annual growth rate of 73% between 2015 and 2030. In the longer term, we expect the market to continue to rise steadily with high adoption rates of existing FMTs and emergence of novel microbiome related products.
- Additional analysis suggeststhat metabolic disorders and gastrointestinal (GI) disorders are the key therapeutic areas likely to garner a significant proportion of the overall market.

Companies Mentioned

- 4D Pharma
- AOBiome
- APC Microbiome Institute
- AbbVie
- ActoGeniX
- Admera Health
- Advanced Technology Ventures
- Advancing Bio
- AgBiome
- Assembly Biosciences
- Avid Biotics
- Azitra
- BTER Foundation
- Baylor College of Medicine
- Beth Israel Deaconess Medical Center
- Bill and Melinda Gates Foundation
- BioAster Technology Research Institute
- BioBalance Corporation
- BioConsortia
- BioGaia
- Biocartis
- Biomecite Diagnostics
- Boston Children's Hospital
- Boston Medical Center
- Brigham and Women's Hospital
- Bright Medicine Clinic
- Broad Institute
- C3 Jian
- Cedars-Sinai Medical Center (CSMC)
- Center for Biologics Evaluation and Research (CBER)
- Center for Disease Control and Prevention
- Cipac Therapeutics
- Cleveland Clinic
- Commonwealth Scientific and Industrial Research Organisation(CSIRO)
- Companion PBx
- Concorde Medical Group
- Crohn's and Colitis Foundation of America (CCFA)
- Da Volterra
- Dairy Innovation Australia Limited (DIAL)
- Danisco
- Debiopharm
- Defence Advanced Research Projects Agency (DARPA)
- Dermala
- Duke University
- Enso Ventures
- Enterologics
- Enterome BioScience
- Epibiome
- Epiva Therapeutics
- Evelo Therapeutics
- Evolve Biosystems
- Evotec
- ExeGi Pharma
- FUJIFILM Diosynth Biotechnologies
- Flagship Ventures
- Food and Agricultural Organisation (FAO)
- GMU Microbiome Analysis Center (MBAC)
- GT Biologics
- Gallinee
- Genetic Analysis
- Genewiz
- Gustave Roussy
- Hadassah Medical Center
- Hospital Oberndorf
- Human Longevity
- Hy Laboratories
- INRA National Institute for Agronomic Research
- Igen Biotech Group
- Illumina Accelerator
- Immune Biologics
- Immuron
- Indiana University
- Inocucor Technologies
- Inserm
- Institut De Recherche Pour Le Developent (IRD)
- Institut Merieux
- Institute for Biomedical Research Dr JosepTrueta of Girona
- Institute of Cardio metabolism and Nutrition (ICAN)
- International Agency for Research on Cancer (IARC)
- Intrexon
- J. Craig Venter Institute
- Janssen
- Johnson & Johnson Innovation Center
- KOLUPOHAKU TECHNOLOGIES (KPT)
- Kindstar Global
- Lille Teaching Hospital (CHRU)
- Lundbeckfond Ventures
- MBcure
- MaaT Pharma
- Macau University of Science and Technology
- Manzo Pharmaceuticals
- Matatu
- Mayo Clinic
- Medical University Innsbruck
- Merck
- Metabiomics
- Metabogen
- Metabolon
- Metanome
- Metrodora Therapeutics
- MiOmics
- MicroBiome Therapeutics
- Microbiome
- Microbiome Diagnostics
- Microbiota Company
- Miyarisan Pharmaceutical
- Monarch Labs
- Monash University
- MonterFiore Medical Research Center of Connecticut
- Morgenthaler
- MyBiotics
- NIZO Food Research
- National Center for Health Statistics (NCHS)
- National Health Service (NHS)
- National Institute of Allergic and Infectious Diseases (NIAID)
- National Institute of Health (NIH)
- Novartis
- OmniBiome Therapeutics
- One Way Liver
- OpenBiome
- OptiBiotix Health
- Oragenics
- Osel
- OxThera
- Pasteur Institute
- Pfizer
- Pivot Bio
- Prev AbR
- Procarta Biosystems
- PureFlora
- Quorum Innovations
- Rebiotix
- Ritter Pharmaceuticals
- Rush University Medical Center
- Second Genome
- Sen Nuo Wei Biotechnology
- Seres Therapeutics
- Servier
- Seventure
- Shire
- Shoreline Biome
- Sigma-Tau Pharmaceuticals
- SporeGen
- Swecure
- Symberix
- Symbiota
- Symbiotix Biotherapies
- Synlogic
- Synthetic Biologics
- TargEDys
- Therapeutic Solutions International
- TriPhase Pharmaceuticals
- UAS Labs
- Universal Stabilisation Technologies
- Universite Pierre Et Marie Curie (UPMC)
- University of California, San Diego (UCSD)
- University of Chicago
- University of Guelph
- University of Maryland (UM) Ventures
- University of Rome Tor Vergata
- University of Virginia
- VSL Pharmaceuticals
- Vaiomer
- Vedanta Biosciences
- Virginia Commonwealth University
- ViroPharma Incorporated
- Vithera Pharmaceuticals
- Washington University School of Medicine
- Wavepoint Ventures
- Weizmann Institute
- Whole Biome
- World Gastroenterology Organisation (WGO)
- World Health Organisation (WHO)
- Wyss Institute
- Xycrobe Therapeutics
- Yakult Honsha
- c-LECta


For more information visit http://www.researchandmarkets.com/research/7ft9d9/microbiome



About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

CONTACT: Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Sector: Pharmaceuticals